1315355-93-1 Usage
Description
NG-25 is a compound that possesses the ability to inhibit various kinases, including TGF-beta-activated kinase 1 (TAK1), LYN, mitogen-activated protein kinase (MAP4K2), and Abl kinase activity. Its unique properties make it a potential candidate for various applications in different industries.
Uses
Used in Pharmaceutical Industry:
NG-25 is used as a therapeutic agent for its ability to inhibit TAK1, which plays a role in various cellular processes such as inflammation, immune responses, and cancer progression. By targeting TAK1, NG-25 may have potential applications in treating conditions related to these processes.
NG-25 is also used as a kinase inhibitor for its ability to inhibit LYN, MAP4K2, and Abl kinase activity. These kinases are involved in various signaling pathways that contribute to the development and progression of cancers. As a result, NG-25 may be utilized in the development of targeted cancer therapies.
Used in Research Applications:
In the field of research, NG-25 is used as a research tool for studying the roles of TAK1, LYN, MAP4K2, and Abl kinases in cellular processes. By inhibiting these kinases, researchers can gain insights into the molecular mechanisms underlying various diseases and conditions, potentially leading to the discovery of new therapeutic targets and treatments.
Used in Drug Development:
NG-25 serves as a starting point for the development of new drugs targeting TAK1, LYN, MAP4K2, and Abl kinases. Its ability to inhibit these kinases makes it a valuable compound for designing and optimizing more potent and selective inhibitors with improved pharmacological properties for therapeutic use in various diseases, including cancer and inflammatory conditions.
Biochem/physiol Actions
NG25 is potent multiple kinase inhibitor belonging to type II kinase inhibitors class that binds to kinase ATP binding pocket at not ready to catalyze conformation. NG25 is used as a potent dual inhibitor of TAK1 (TGFβ-Activated Kinase 1, MAP3K7) and MAP4K2 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2; GCK) kinases. NG25 inhibits the activation of IKKa/IKKb and prevents the secretion of type 1 IFNs by TLR2 and TLR9 agonist.
Check Digit Verification of cas no
The CAS Registry Mumber 1315355-93-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,5,3,5 and 5 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1315355-93:
(9*1)+(8*3)+(7*1)+(6*5)+(5*3)+(4*5)+(3*5)+(2*9)+(1*3)=141
141 % 10 = 1
So 1315355-93-1 is a valid CAS Registry Number.
1315355-93-1Relevant articles and documents
Discovery of type II inhibitors of tgfβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)
Tan, Li,Nomanbhoy, Tyzoon,Gurbani, Deepak,Patricelli, Matthew,Hunter, John,Geng, Jiefei,Herhaus, Lina,Zhang, Jianming,Pauls, Eduardo,Ham, Youngjin,Choi, Hwan Geun,Xie, Ting,Deng, Xianming,Buhrlage, Sara J.,Sim, Taebo,Cohen, Philip,Sapkota, Gopal,Westover, Kenneth D.,Gray, Nathanael S.
, p. 183 - 196 (2015/03/04)
We developed a pharmacophore model for type II inhibitors that was used to guide the construction of a library of kinase inhibitors. Kinome-wide selectivity profiling of the library resulted in the identification of a series of 4-substituted 1H-pyrrolo[2,
